Pleasanton, CA, United States of America

Charles Alcorn

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Roche Molecular Systems, Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles Alcorn. Retrieved from https://idiyas.com/inventor/charles-alcorn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Charles Alcorn and His Patent Work.

Introduction

Charles Alcorn is an inventor based in Pleasanton, California. The provided information lists 1 patent associated with him and identifies Roche Molecular Systems, Inc. as his company.

Latest Patents

Alcorn’s listed patent is “Display screen or portion thereof with graphical user interface for patient pathway reconstruction and aggregation.” The patent concerns a graphical user interface designed to support the reconstruction and aggregation of patient pathways.

Career Highlights

The available information connects Alcorn’s patent work with Roche Molecular Systems, Inc. No further details about his role or career history were provided.

Collaborations

Celia Bel and Ju Zhang are identified as Alcorn’s coworkers. Their names are provided as professional associations, without further details about specific joint projects.

Conclusion

Charles Alcorn’s listed invention focuses on a graphical interface for patient pathway reconstruction and aggregation, reflecting his connection to patent activity at Roche Molecular Systems, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…